|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 98.16 CHF | -0.28% |
|
-0.45% | +15.66% |
| 09-11 | NOVARTIS AG : Gets a Buy rating from UBS | ZD |
| 09-06 | EXECUTIVE CHANGES: Invinity replaces CEO; Gulf Keystone chair dies | AN |
Aug 7 (Reuters) - The U.S. Food and Drug Administration has approved the use of Novartis' drug to treat patients with a type of kidney disease, the health regulator's website showed on Wednesday. (Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 206.20 SEK | -0.58% | -0.58% | 1.09B | ||
| 98.16 CHF | -0.28% | -0.45% | 234B | ||
| 13.48 USD | +6.98% | +22.77% | 1.03B | ||
